Literature DB >> 16322113

Rapid-infusion rituximab in lymphoma treatment.

M Provencio, S Cerdeira, F Bonilla, A Sánchez, P España.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16322113     DOI： 10.1093/annonc/mdj103

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

1.  Review of the safety and feasibility of rapid infusion of rituximab.

Authors:  Jill Atmar
Journal:  J Oncol Pract       Date:  2010-03       Impact factor: 3.840

2.  Rapid infusion with rituximab: short term safety in systemic autoimmune diseases.

Authors:  Janni Lisander Larsen; Soren Jacobsen
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

3.  A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.

Authors:  Tatsuya Hayama; Katsuhiro Miura; Akihiro Uchiike; Masaru Nakagawa; Daisuke Tsutsumi; Masashi Sakagami; Yoshikazu Yoshida; Masami Takei
Journal:  Int J Clin Pharm       Date:  2017-01-31

4.  Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.

Authors:  Meryem Can; Fatma Alibaz-Öner; Sibel Yılmaz-Öner; Pamir Atagündüz; Nevsun İnanç; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2012-10-11       Impact factor: 2.980

5.  A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.

Authors:  Joen Chiang; Alexandre Chan; Vivianne Shih; Siew Wan Hee; Miriam Tao; Soon Thye Lim
Journal:  Int J Hematol       Date:  2010-05-13       Impact factor: 2.490

6.  Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen.

Authors:  Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2016-12

7.  A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.

Authors:  Daisuke Tsutsumi; Tatsuya Hayama; Katsuhiro Miura; Akihiro Uchiike; Shinya Tsuboi; Susumu Otsuka; Yoshihiro Hatta; Yukinaga Kishikawa
Journal:  Int J Clin Pharm       Date:  2021-12-11

8.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal:  Ann Rheum Dis       Date:  2011-03-06       Impact factor: 19.103

9.  Rapid-Infusion Rituximab in a Pediatric Population.

Authors:  Kelly J Gaffney; Elizabeth M Dahl; Michael P Stanton; Elizabeth Starek; Anthony S Zembillas
Journal:  J Pediatr Pharmacol Ther       Date:  2020

10.  Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Authors:  Jeffrey Bryan; Gautam Borthakur
Journal:  Ther Clin Risk Manag       Date:  2010-12-22       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.